Of course we might always get good news before that, Bucweey. Dr. Jay and Hoffman both described a meeting with the FDA for which they'd prepared a briefing book. The ideal news for me would be that the protocol for the CRC trial has been changed to include an ICI option within the study itself. But there are also other positive results that meeting could bring -- orphan drug status, for example, as Hoffman mentioned.